TriSalus Life Sciences (TLSI) News Today $4.07 -0.05 (-1.21%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from AnalystsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has earned a consensus rating of "Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the companyNovember 20 at 3:17 AM | marketbeat.comHead-To-Head Survey: TriSalus Life Sciences (TLSI) versus Its CompetitorsNovember 19 at 3:48 AM | americanbankingnews.comComparing TriSalus Life Sciences (TLSI) & Its CompetitorsNovember 17, 2024 | americanbankingnews.comTriSalus Life Sciences price target lowered to $11 from $12 at CanaccordNovember 16, 2024 | markets.businessinsider.comTriSalus Life Sciences: Strong Growth and Strategic Partnerships Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comRoth MKM Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)November 15, 2024 | markets.businessinsider.comCanaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock PriceCanaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Friday.November 15, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Upgraded to "Strong-Buy" at Roth CapitalNovember 15, 2024 | americanbankingnews.comTriSalus Life Sciences sees FY25 revenue growth ‘more than 50%’November 15, 2024 | markets.businessinsider.comRoth Mkm Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI)November 14, 2024 | americanbankingnews.comWhat is Roth Capital's Estimate for TLSI Q3 Earnings?November 14, 2024 | americanbankingnews.comBrokers Offer Predictions for TLSI Q3 EarningsTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Equities researchers at Roth Capital issued their Q3 2024 earnings estimates for shares of TriSalus Life Sciences in a research report issued on Monday, November 11th. Roth Capital analyst J. Wittes forecasts that the company will post eaNovember 13, 2024 | marketbeat.comTriSalus Life Sciences initiated with a Buy at Roth MKMNovember 13, 2024 | markets.businessinsider.comRoth MKM Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy RecommendationNovember 12, 2024 | msn.comTriSalus Life Sciences: Promising Growth with Innovative TriNav Catheter and TL-9 AntagonistNovember 12, 2024 | markets.businessinsider.comTriSalus Life Sciences teams with Geo-Med to expand TriNav availability to VANovember 12, 2024 | markets.businessinsider.comRoth Capital Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to "Strong-Buy"Roth Capital upgraded TriSalus Life Sciences to a "strong-buy" rating in a research report on Monday.November 12, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Roth MkmRoth Mkm began coverage on shares of TriSalus Life Sciences in a research note on Monday. They issued a "buy" rating and a $11.00 target price for the company.November 11, 2024 | marketbeat.comTriSalus Life Sciences (TLSI) to Release Quarterly Earnings on ThursdayTriSalus Life Sciences (NASDAQ:TLSI) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643229)November 7, 2024 | marketbeat.comTriSalus Life Sciences (TLSI) Set to Announce Quarterly Earnings on ThursdayTriSalus Life Sciences (NASDAQ:TLSI) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643229)November 7, 2024 | marketbeat.comTriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference CallOctober 31, 2024 | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 21.3% in OctoberTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 62,100 shares, an increase of 21.3% from the September 30th total of 51,200 shares. Based on an average daily volume of 47,100 shares, the short-interest ratio is presently 1.3 days. Currently, 1.4% of the shares of the company are sold short.October 28, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Stock, Short Interest ReportOctober 26, 2024 | benzinga.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of "Buy" by AnalystsShares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have received a consensus recommendation of "Buy" from the five research firms that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 1 yeaOctober 26, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Upgraded to Strong-Buy at Northland CapmkNorthland Capmk raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Friday.October 26, 2024 | marketbeat.comNorthland Securities Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI)Northland Securities started coverage on TriSalus Life Sciences in a research report on Friday. They set an "outperform" rating and a $12.50 target price for the company.October 25, 2024 | marketbeat.comTriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 14, 2024 | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 62.5% in SeptemberTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 51,200 shares, a growth of 62.5% from the September 15th total of 31,500 shares. Approximately 1.0% of the company's shares are sold short. Based on an average daily volume of 46,000 shares, the days-to-cover ratio is currently 1.1 days.October 12, 2024 | marketbeat.comTriSalus Life Sciences Inc.October 10, 2024 | wsj.comTriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory BoardSeptember 26, 2024 | finance.yahoo.comTriSalus Life Sciences, Inc. (TLSI)September 25, 2024 | finance.yahoo.comHighbridge Capital Management LLC Invests $1.18 Million in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 214,545 shares of the companySeptember 19, 2024 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Research Coverage Started at OppenheimerOppenheimer started coverage on TriSalus Life Sciences in a research report on Monday. They set an "outperform" rating and a $10.00 target price for the company.September 16, 2024 | marketbeat.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest UpdateTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the recipient of a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 32,900 shares, a decline of 20.0% from the August 15th total of 41,100 shares. Based on an average daily trading volume, of 40,400 shares, the short-interest ratio is currently 0.8 days. Currently, 0.6% of the company's shares are short sold.September 15, 2024 | marketbeat.comInsider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Acquires 7,520 Shares of StockSeptember 14, 2024 | insidertrades.comTriSalus Life Sciences Inc (TLSI) CEO Buys SharesSeptember 14, 2024 | finance.yahoo.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Buys 7,520 SharesTriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary T. Szela bought 7,520 shares of TriSalus Life Sciences stock in a transaction on Thursday, September 12th. The shares were bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the acquisition, the chief executive officer now owns 377,382 shares of the company's stock, valued at approximately $1,962,386.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.September 13, 2024 | marketbeat.comMary T. Szela Buys 5,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockSeptember 13, 2024 | insidertrades.comTriSalus Life Sciences, Inc. (TLSIW)August 21, 2024 | uk.finance.yahoo.comTriSalus stock holds Buy rating with $11 targetAugust 18, 2024 | investing.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | msn.comTriSalus Reports Q2 2024 Financial Results and Business UpdateAugust 15, 2024 | finanznachrichten.deTLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024August 15, 2024 | msn.comTriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference CallAugust 1, 2024 | stockhouse.comCanaccord Genuity Group Reiterates Buy Rating for TriSalus Life Sciences (NASDAQ:TLSI)Canaccord Genuity Group reissued a "buy" rating and set a $12.00 price objective on shares of TriSalus Life Sciences in a report on Thursday.June 27, 2024 | marketbeat.comTriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to WarrantsJune 26, 2024 | businesswire.comShort Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Grows By 140.2%TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the target of a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 413,400 shares, a growth of 140.2% from the May 15th total of 172,100 shares. Based on an average daily volume of 48,400 shares, the short-interest ratio is presently 8.5 days. Approximately 15.1% of the shares of the company are short sold.June 13, 2024 | marketbeat.comTriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual MeetingJune 3, 2024 | businesswire.comTriSalus Life Sciences (NASDAQ:TLSI) Receives New Coverage from Analysts at Canaccord Genuity GroupCanaccord Genuity Group began coverage on TriSalus Life Sciences in a research report on Thursday. They set a "buy" rating and a $12.00 price target on the stock.May 30, 2024 | marketbeat.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to WarrantsMay 24, 2024 | businesswire.com Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO TLSI Media Mentions By Week TLSI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TLSI News Sentiment▼0.450.45▲Average Medical News Sentiment TLSI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TLSI Articles This Week▼111▲TLSI Articles Average Week Get TriSalus Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Treace Medical Concepts News Today Perspective Therapeutics News Today Tactile Systems Technology News Today ZimVie News Today AVITA Medical News Today Semler Scientific News Today Nano-X Imaging News Today CVRx News Today Sanara MedTech News Today Delcath Systems News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TLSI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLSI Stock Alerts